SEARCH

SEARCH BY CITATION

References

  • 1
    Riley CM, Day RL, Greeley DM & Langford WS (1949) Central autonomic dysfunction with defective lacrimation; report of five cases. Pediatrics 3, 468478.
  • 2
    Axelrod FB, Nachtigal R & Dancis J (1974) Familial dysautonomia: diagnosis, pathogenesis and management. Adv Pediatr 21, 7596.
  • 3
    Axelrod FB (1996) Familial Dysautonomia. In Primer on the Autonomic Nervous System (Robertson D, Low PA & Polinsky RJ, eds), pp. 242249. Academic Press, San Diego, CA.
  • 4
    Rubin BY & Anderson SL (2008) The molecular basis of familial dysautonomia: overview, new discoveries and implications for directed therapies. Neuromolecular Med 10, 148156.
  • 5
    Anderson SL, Coli R, Daly IW, Kichula EA, Rork MJ, Volpi SA, Ekstein J & Rubin BY (2001) Familial dysautonomia is caused by mutations of the IKAP gene. Am J Hum Genet 68, 753758.
  • 6
    Slaugenhaupt SA, Blumenfeld A, Gill SP, Leyne M, Mull J, Cuajungco MP, Liebert CB, Chadwick B, Idelson M, Reznik L et al. (2001) Tissue-specific expression of a splicing mutation in the IKBKAP gene causes familial dysautonomia. Am J Hum Genet 68, 598605.
  • 7
    Cohen L, Henzel WJ & Baeuerle PA (1998) IKAP is a scaffold protein of the IkappaB kinase complex. Nature 395, 292296.
  • 8
    Otero G, Fellows J, Li Y, de Bizemont T, Dirac AM, Gustafsson CM, Erdjument-Bromage H, Tempst P & Svejstrup JQ (1999) Elongator, a multisubunit component of a novel RNA polymerase II holoenzyme for transcriptional elongation. Mol Cell 3, 109118.
  • 9
    Krappmann D, Hatada EN, Tegethoff S, Li J, Klippel A, Giese K, Baeuerle PA & Scheidereit C (2000) The I kappa B kinase (IKK) complex is tripartite and contains IKK gamma but not IKAP as a regular component. J Biol Chem 275, 2977929787.
  • 10
    Hawkes NA, Otero G, Winkler GS, Marshall N, Dahmus ME, Krappmann D, Scheidereit C, Thomas CL, Schiavo G, Erdjument-Bromage H et al. (2002) Purification and characterization of the human elongator complex. J Biol Chem 277, 30473052.
  • 11
    Holmberg C, Katz S, Lerdrup M, Herdegen T, Jäättelä M, Aronheim A & Kallunki T (2002) A novel specific role for I kappa B kinase complex-associated protein in cytosolic stress signaling. J Biol Chem 277, 3191831928.
  • 12
    Chen YT, Hims MM, Shetty RS, Mull J, Liu L, Leyne M & Slaugenhaupt SA (2009) Loss of mouse IKBKAP, a subunit of elongator, leads to transcriptional deficits and embryonic lethality that can be rescued by human IKBKAP. Mol Cell Biol 29, 736744.
  • 13
    Mehlgarten C, Jablonowski D, Wrackmeyer U, Tschitschmann S, Sondermann D, Jäger G, Gong Z, Byström AS, Schaffrath R & Breunig KD (2010) Elongator function in tRNA wobble uridine modification is conserved between yeast and plants. Mol Microbiol 76, 10821094.
  • 14
    Rahl PB, Chen CZ & Collins RN (2005) Elp1p, the yeast homolog of the FD disease syndrome protein, negatively regulates exocytosis independently of transcriptional elongation. Mol Cell 18, 841853.
  • 15
    Johansen LD, Naumanen T, Knudsen A, Westerlund N, Gromova I, Junttila M, Nielsen C, Bøttzauw T, Tolkovsky A, Westermarck J et al. (2008) IKAP localizes to membrane ruffles with filamin A and regulates actin cytoskeleton organization and cell migration. J Cell Sci 121, 854864.
  • 16
    Anderson SL, Qiu J & Rubin BY (2003) Tocotrienols induce IKBKAP expression: a possible therapy for familial dysautonomia. Biochem Biophys Res Commun 306, 303309.
  • 17
    Anderson SL, Qiu J & Rubin BY (2003) EGCG corrects aberrant splicing of IKAP mRNA in cells from patients with familial dysautonomia. Biochem Biophys Res Commun 310, 627633.
  • 18
    Slaugenhaupt SA, Mull J, Leyne M, Cuajungco MP, Gill SP, Hims MM, Quintero F, Axelrod FB & Gusella JF (2004) Rescue of a human mRNA splicing defect by the plant cytokinin kinetin. Hum Mol Genet 13, 429436.
  • 19
    Lee G, Papapetrou EP, Kim H, Chambers SM, Tomishima MJ, Fasano CA, Ganat YM, Menon J, Shimizu F, Viale A et al. (2009) Modeling pathogenesis and treatment of familial dysautonomia using patient specific iPSCs. Nature 461, 402406.
  • 20
    Boone N, Loriod B, Bergon A, Sbai O, Formisano-Tréziny C, Gabert J, Khrestchatisky M, Nguyen C, Féron F, Axelrod FB et al. (2010) Olfactory stem cells, a new cellular model for studying molecular mechanisms underlying familial dysautonomia. PLoS One 5, e15590.
  • 21
    Keren H, Donyo M, Zeevi D, Maayan C, Pupko T & Ast G (2010) Phosphatidylserine increases IKBKAP levels in familial dysautonomia cells. PLoS One 5, e15884.
  • 22
    Lee G, Ramirez CN, Kim H, Zeltner N, Liu B, Radu C, Bhinder B, Kim YJ, Choi IY, Mukherjee-Clavin B et al. (2012) Large-scale screening using familial dysautonomia induced pluripotent stem cells identifies compounds that rescue IKBKAP expression. Nat Biotechnol 30, 12441248.
  • 23
    Anderson SL & Rubin BY (2005) Tocotrienols reverse IKAP and monoamine oxidase deficiencies in familial dysautonomia. Biochem Biophys Res Commun 336, 150156.
  • 24
    Gold-von Simson G & Axelrod FB (2006) Familial dysautonomia: update and recent advances. Curr Probl Pediatr Adolesc Health Care 36, 218237.
  • 25
    Rubin BY, Anderson SL & Kapás L (2008) Can the therapeutic efficacy of tocotrienols in neurodegenerative familial dysautonomia patients be measured clinically? Antioxid Redox Signal 10, 837841.
  • 26
    Anderson SL, Liu B, Qiu J, Sturm AJ, Schwartz JA, Peters AJ, Sullivan KA & Rubin BY (2012) Nutraceutical-mediated restoration of wild-type levels of IKBKAP-encoded IKAP protein in familial dysautonomia-derived cells. Mol Nutr Food Res 56, 570579.
  • 27
    McPhie DC (2004) Old drugs, new uses: solving a Hatch−Waxman patent predicament. Food Drug Law J 59, 155168.
  • 28
    Aronson JK (2007) Old drugs − new uses. Br J Clin Pharmacol 64, 563565.
  • 29
    Chong CR & Sullivan DJ Jr (2007) New uses for old drugs. Nature 448, 645646.
  • 30
    Smith TW, Butler VP Jr & Haber E (1969) Determination of therapeutic and toxic serum digoxin concentrations by radioimmunoassay. N Engl J Med 281, 12121216.
  • 31
    Ibrahim EC, Hims MM, Shomron N, Burge CB, Slaugenhaupt SA & Reed R (2007) Weak definition of IKBKAP exon 20 leads to aberrant splicing in familial dysautonomia. Hum Mutat 28, 4153.
  • 32
    Hims MM, Ibrahim EC, Leyne M, Mull J, Liu L, Lazaro C, Shetty RS, Gill S, Gusella JF, Reed R et al. (2007) Therapeutic potential and mechanism of kinetin as a treatment for the human splicing disease familial dysautonomia. J Mol Med 85, 149161.
  • 33
    Stamm S, Riethoven JJ, Le Texier V, Gopalakrishnan C, Kumanduri V, Tang Y, Barbosa-Morais NL & Thanaraj TA (2006) ASD: a bioinformatics resource on alternative splicing. Nucleic Acids Res 34, D4655.
  • 34
    Hims MM, Shetty RS, Pickel J, Mull J, Leyne M, Liu L, Gusella JF & Slaugenhaupt SA (2007) A humanized IKBKAP transgenic mouse models a tissue-specific human splicing defect. Genomics 90, 389396.
  • 35
    Dietrich P, Alli S, Shanmugasundaram R & Dragatsis I (2012) IKAP expression levels modulate disease severity in a mouse model of familial dysautonomia. Hum Mol Genet 21, 50785090.
  • 36
    Stoilov P, Lin CH, Damoiseaux R, Nikolic J & Black DL (2008) A high-throughput screening strategy identifies cardiotonic steroids as alternative splicing modulators. Proc Natl Acad Sci USA 105, 1121811223.
  • 37
    Änkö M-L, Müller-McNicoll M, Brandl H, Curk T, Gorup C, Henry I, Ule J & Neugebauer KM (2012) The RNA-binding landscapes of two SR proteins reveal unique functions and binding to diverse RNA classes. Genome Biol 13, R17.
  • 38
    House AE & Lynch KW (2008) Regulation of alternative splicing: more than just the ABCs. J Biol Chem 283, 12171221.
  • 39
    Erkelenz S, Mueller WF, Evans MS, Busch A, Schöneweis K, Hertel KJ & Schaal H (2013) Position-dependent splicing activation and repression by SR and hnRNP proteins rely on common mechanisms. RNA 19, 96102.
  • 40
    Sen S, Talukdar I & Webster NJ (2009) SRp20 and CUG-BP1 modulate insulin receptor exon 11 alternative splicing. Mol Cell Biol 29, 871880.
  • 41
    Mabon SA & Misteli T (2005) Differential recruitment of pre-mRNA splicing factors to alternatively spliced transcripts in vivo. PLoS Biol 3, e374.
  • 42
    Galiana-Arnoux D, Lejeune F, Gesnel MC, Stevenin J, Breathnach R & Del Gatto-Konczak F (2003) The CD44 alternative v9 exon contains a splicing enhancer responsive to the SR proteins 9G8, ASF/SF2, and SRp20. J Biol Chem 278, 3294332953.
  • 43
    Ling IF & Estus S (2010) Role of SFRS13A in low-density lipoprotein receptor splicing. Hum Mutat 31, 702709.
  • 44
    Gonçalves V, Matos P & Jordan P (2009) Antagonistic SR proteins regulate alternative splicing of tumor-related Rac1b downstream of the PI3-kinase and Wnt pathways. Hum Mol Gene 18, 36963707.
  • 45
    Gromak N, Talotti G, Proudfoot NJ & Pagani F (2008) Modulating alternative splicing by cotranscriptional cleavage of nascent intronic RNA. RNA 14, 359366.
  • 46
    Sterne-Weiler T, Howard J, Mort M, Cooper DN & Sanford JR (2011) Loss of exon identity is a common mechanism of human inherited disease. Genome Res 21, 15631571.
  • 47
    Lukas J, Gao DQ, Keshmeshian M, Wen WH, Tsao-Wei D, Rosenberg S & Press MF (2001) Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer. Cancer Res 61, 32123219.
  • 48
    Feltes CM, Kudo A, Blaschuk O & Byers SW (2002) An alternatively spliced cadherin-11 enhances human breast cancer cell invasion. Cancer Res 62, 66886697.
  • 49
    Ghigna C, Valacca C & Biamonti G (2008) Alternative splicing and tumor progression. Curr Genomics 9, 556570.
  • 50
    Brinkman BM (2004) Splice variants as cancer biomarkers. Clin Biochem 37, 584594.
  • 51
    Grosso AR, Martins S & Carmo-Fonseca M (2008) The emerging role of splicing factors in cancer. EMBO Rep 9, 10871093.
  • 52
    Stickeler E, Kittrell F, Medina D & Berget SM (1999) Stage-specific changes in SR splicing factors and alternative splicing in mammary tumorigenesis. Oncogene 18, 35743582.
  • 53
    Jia R, Li C, McCoy JP, Deng CX & Zheng ZM (2010) SRp20 is a proto-oncogene critical for cell proliferation and tumor induction and maintenance. Int J Biol Sci 6, 806826.
  • 54
    He X, Arslan AD, Pool MD, Ho TT, Darcy KM, Coon JS & Beck WT (2011) Knockdown of splicing factor SRp20 causes apoptosis in ovarian cancer cells and its expression is associated with malignancy of epithelial ovarian cancer. Oncogene 30, 356365.
  • 55
    Stenkvist B, Bengtsson E, Eriksson O, Holmquist J, Nordin B & Westman-Naeser S (1979) Cardiac glycosides and breast cancer. Lancet 1, 563.
  • 56
    Newman RA, Yang P, Pawlus AD & Block KI (2008) Cardiac glycosides as novel cancer therapeutic agents. Mol Interv 8, 3649.
  • 57
    López-Lázaro M (2007) Digitoxin as an anticancer agent with selectivity for cancer cells: possible mechanisms involved. Expert Opin Ther Targets 11, 10431053.
  • 58
    Beheshti Zavareh R, Lau KS, Hurren R, Datti A, Ashline DJ, Gronda M, Cheung P, Simpson CD, Liu W, Wasylishen AR et al. (2008) Inhibition of the sodium/potassium ATPase impairs N-glycan expression and function. Cancer Res 68, 66886697.
  • 59
    Zhang H, Qian DZ, Tan YS, Lee K, Gao P, Ren YR, Rey S, Hammers H, Chang D, Pili R et al. (2008) Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. Proc Natl Acad Sci USA 105, 1957919586.
  • 60
    Hashimoto S, Jing Y, Kawazoe N, Masuda Y, Nakajo S, Yoshida T, Kuroiwa Y & Nakaya K (1997) Bufalin reduces the level of topoisomerase II in human leukemia cells and affects the cytotoxicity of anticancer drugs. Leuk Res 21, 875883.
  • 61
    Mijatovic T, De Nève N, Gailly P, Mathieu V, Haibe-Kains B, Bontempi G, Lapeira J, Decaestecker C, Facchini V & Kiss R (2008) Nucleolus and c-Myc: potential targets of cardenolide-mediated antitumor activity. Mol Cancer Ther 7, 12851296.
  • 62
    Xie Z (2003) Molecular mechanisms of Na/K-ATPase-mediated signal transduction. Ann N Y Acad Sci 986, 497503.
  • 63
    Frese S, Frese-Schaper M, Andres AC, Miescher D, Zumkehr B & Schmid RA (2006) Cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5. Cancer Res 66, 58675874.
  • 64
    Manna SK, Sreenivasan Y & Sarkar A (2006) Cardiac glycoside inhibits IL-8-induced biological responses by downregulating IL-8 receptors through altering membrane fluidity. J Cell Physiol 207, 195207.
  • 65
    Wang Z, Zheng M, Li Z, Li R, Jia L, Xiong X, Southall N, Wang S, Xia M, Austin CP et al. (2009) Cardiac glycosides inhibit p53 synthesis by a mechanism relieved by Src or MAPK inhibition. Cancer Res 69, 65566564.
  • 66
    Prassas I, Karagiannis GS, Batruch I, Dimitromanolakis A, Datti A & Diamandis EP (2011) Digitoxin-induced cytotoxicity in cancer cells is mediated through distinct kinase and interferon signaling networks. Mol Cancer Ther 10, 20832093.
  • 67
    Rubin BY, Anderson SL, Sullivan SA, Williamson BD, Carswell EA & Old LJ (1985) Purification and characterization of a human tumor necrosis factor from the LuKII cell line. Proc Natl Acad Sci USA 82, 66376641.